Cargando…
Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB
BACKGROUND: Cancer stem cell model suggested that tumor progression is driven by the overpopulation of cancer stem cells and eradicating or inhibiting the symmetric division of cancer stem cells would become the most important therapeutic strategy. However, clinical evidence for this hypothesis is s...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715381/ https://www.ncbi.nlm.nih.gov/pubmed/19583834 http://dx.doi.org/10.1186/1479-5876-7-56 |
_version_ | 1782169768424374272 |
---|---|
author | Li, Chun-Yan Li, Bao-Xiu Liang, Yi Peng, Rui-Qing Ding, Ya Xu, Da-Zhi Zhang, Xin Pan, Zhi-Zhong Wan, De-Sen Zeng, Yi-Xin Zhu, Xiao-Feng Zhang, Xiao-Shi |
author_facet | Li, Chun-Yan Li, Bao-Xiu Liang, Yi Peng, Rui-Qing Ding, Ya Xu, Da-Zhi Zhang, Xin Pan, Zhi-Zhong Wan, De-Sen Zeng, Yi-Xin Zhu, Xiao-Feng Zhang, Xiao-Shi |
author_sort | Li, Chun-Yan |
collection | PubMed |
description | BACKGROUND: Cancer stem cell model suggested that tumor progression is driven by the overpopulation of cancer stem cells and eradicating or inhibiting the symmetric division of cancer stem cells would become the most important therapeutic strategy. However, clinical evidence for this hypothesis is still scarce. To evaluate the overpopulation hypothesis of cancer stem cells the association of percentage of CD133(+ )tumor cells with clinicopathological parameters in colon cancer was investigated since CD133 is a putative cancer stem cell marker shared by multiple solid tumors. PATIENTS AND METHODS: Tumor tissues matched with adjacent normal tissues were collected from 104 stage IIIB colon cancer patients who were subject to radical resection between January, 1999 to July, 2003 in this center. The CD133 expression was examined with immunohistochemical staining. The correlation of the percentage of CD133(+ )cell with clinicopathological parameters and patients' 5-year survival was analyzed. RESULTS: The CD133(+ )cells were infrequent and heterogeneous distribution in the cancer tissue. Staining of CD133 was localized not only on the glandular-luminal surface of cancer cells but also on the invasive budding and the poorly differentiated tumors with ductal structures. Both univariate and multivariate survival analysis revealed that the percentage of CD133(+ )cancer cells and the invasive depth of tumor were independently prognostic. The patients with a lower percentage of CD133(+ )cancer cells (less than 5%) were strongly associated with a higher 5-year survival rate than those with a higher percentage of CD133(+ )cancer cells (greater than or equal to 55%). Additionally, no correlation was obtained between the percentage of CD133(+ )cancer cells and the other clinicopathological parameters including gender, age, site of primary mass, pathologic types, grades, and invasive depth. CONCLUSION: The fact that a higher percentage CD133(+ )cells were strongly associated with a poorer prognosis in patients with locally advanced colon cancer implicated that CD133(+ )cancer cells contribute to the tumor progression, and the overpopulation hypothesis of cancer stem cell seems reasonable. |
format | Text |
id | pubmed-2715381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27153812009-07-25 Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB Li, Chun-Yan Li, Bao-Xiu Liang, Yi Peng, Rui-Qing Ding, Ya Xu, Da-Zhi Zhang, Xin Pan, Zhi-Zhong Wan, De-Sen Zeng, Yi-Xin Zhu, Xiao-Feng Zhang, Xiao-Shi J Transl Med Research BACKGROUND: Cancer stem cell model suggested that tumor progression is driven by the overpopulation of cancer stem cells and eradicating or inhibiting the symmetric division of cancer stem cells would become the most important therapeutic strategy. However, clinical evidence for this hypothesis is still scarce. To evaluate the overpopulation hypothesis of cancer stem cells the association of percentage of CD133(+ )tumor cells with clinicopathological parameters in colon cancer was investigated since CD133 is a putative cancer stem cell marker shared by multiple solid tumors. PATIENTS AND METHODS: Tumor tissues matched with adjacent normal tissues were collected from 104 stage IIIB colon cancer patients who were subject to radical resection between January, 1999 to July, 2003 in this center. The CD133 expression was examined with immunohistochemical staining. The correlation of the percentage of CD133(+ )cell with clinicopathological parameters and patients' 5-year survival was analyzed. RESULTS: The CD133(+ )cells were infrequent and heterogeneous distribution in the cancer tissue. Staining of CD133 was localized not only on the glandular-luminal surface of cancer cells but also on the invasive budding and the poorly differentiated tumors with ductal structures. Both univariate and multivariate survival analysis revealed that the percentage of CD133(+ )cancer cells and the invasive depth of tumor were independently prognostic. The patients with a lower percentage of CD133(+ )cancer cells (less than 5%) were strongly associated with a higher 5-year survival rate than those with a higher percentage of CD133(+ )cancer cells (greater than or equal to 55%). Additionally, no correlation was obtained between the percentage of CD133(+ )cancer cells and the other clinicopathological parameters including gender, age, site of primary mass, pathologic types, grades, and invasive depth. CONCLUSION: The fact that a higher percentage CD133(+ )cells were strongly associated with a poorer prognosis in patients with locally advanced colon cancer implicated that CD133(+ )cancer cells contribute to the tumor progression, and the overpopulation hypothesis of cancer stem cell seems reasonable. BioMed Central 2009-07-07 /pmc/articles/PMC2715381/ /pubmed/19583834 http://dx.doi.org/10.1186/1479-5876-7-56 Text en Copyright ©2009 Li et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Li, Chun-Yan Li, Bao-Xiu Liang, Yi Peng, Rui-Qing Ding, Ya Xu, Da-Zhi Zhang, Xin Pan, Zhi-Zhong Wan, De-Sen Zeng, Yi-Xin Zhu, Xiao-Feng Zhang, Xiao-Shi Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB |
title | Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB |
title_full | Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB |
title_fullStr | Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB |
title_full_unstemmed | Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB |
title_short | Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB |
title_sort | higher percentage of cd133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage iiib |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715381/ https://www.ncbi.nlm.nih.gov/pubmed/19583834 http://dx.doi.org/10.1186/1479-5876-7-56 |
work_keys_str_mv | AT lichunyan higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT libaoxiu higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT liangyi higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT pengruiqing higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT dingya higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT xudazhi higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT zhangxin higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT panzhizhong higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT wandesen higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT zengyixin higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT zhuxiaofeng higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib AT zhangxiaoshi higherpercentageofcd133cellsisassociatedwithpoorprognosisincoloncarcinomapatientswithstageiiib |